Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients

Inclusion Criteria:• Males or females undergoing maintenance hemodyalisis, * Age ≥18 year * Clinically stable and receiving adequate hemodialysis defined by a single pool Kt/V≥1.20 or no less than 3 dialysis sessions per week with a total dialysis time ≥12 hour per week for at least 3 month before enrollment, * Diabetic patients must be willing to commence insulin therapy if deemed necessary for plasma glucose control. Exclusion Criteria: * Active malignant disease (defined as less than 5 year since receiving a diagnosis of being malignancy-free) * Critical illness as defined by the need for respiratory or circulatory support (in an intensive care unit) * Active vasculitis * Severe congestive heart failure (New York Heart Association class IV) * Severe chronic systemic infectious or inflammatory disease * Liver disease (defined as serum alanine aminotransferase or aspartate aminotransferase levels greater than three times the upper limit of normal) * Known or suspected allergy to trial product(s) or related products * Treatment with immunosuppressive agents or receipt of any investigational drug within one month preceding screening * Recent or current use of anti-inflammatory corticosteroids agents * A scheduled renal transplantation within the trial period